Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer

Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer

Aim: Tamoxifen (TAM) resistance remains a clinical issue in breast cancer. The authors previously reported that 15-hydroxyprostaglandin dehydrogenase (HPGD) was significantly downregulated in tamoxifen-resistant (TAMr) breast cancer cell lines. Here, the authors investigated the relationship between...

Full description

Bibliographic Details
Main Authors: Milene Volpato, Michele Cummings, Abeer M. Shaaban, Balkees Abderrahman, Mark A. Hull, Philipp Y. Maximov, Bradley M. Broom, Reiner Hoppe, Ping Fan, Hiltrud Brauch, V. Craig Jordan, Valerie Speirs
Format: Article
Language:English
Published: Open Exploration Publishing Inc. 2020-10-01
Series:Exploration of Targeted Anti-tumor Therapy
Subjects:
breast cancer
endocrine resistance
15-hydroxyprostaglandin dehydrogenase
immunohistochemistry
survival
Online Access:https://www.explorationpub.com/Journals/etat/Article/100221

Internet

https://www.explorationpub.com/Journals/etat/Article/100221

Similar Items